X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MYLAN (US) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   MYLAN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
MYLAN
Dec-14
TORRENT PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,7203,819-   
Low Rs1,1342,691-   
Sales per share (Unadj.) Rs394.51,307.2-  
Earnings per share (Unadj.) Rs101.8157.5-  
Cash flow per share (Unadj.) Rs116.3253.5-  
Dividends per share (Unadj.) Rs40.000-  
Dividend yield (eoy) %2.80-  
Book value per share (Unadj.) Rs200.3649.8-  
Shares outstanding (eoy) m169.22378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.62.5 145.2%   
Avg P/E ratio x14.020.7 67.8%  
P/CF ratio (eoy) x12.312.8 95.5%  
Price / Book Value ratio x7.15.0 142.2%  
Dividend payout %39.30-   
Avg Mkt Cap Rs m241,4351,231,502 19.6%   
No. of employees `00010.925.0 43.6%   
Total wages/salary Rs m8,5590-   
Avg. sales/employee Rs Th6,129.619,784.8 31.0%   
Avg. wages/employee Rs Th785.80-   
Avg. net profit/employee Rs Th1,581.32,383.4 66.3%   
INCOME DATA
Net Sales Rs m66,764494,620 13.5%  
Other income Rs m2,156-2,883 -74.8%   
Total revenues Rs m68,920491,737 14.0%   
Gross profit Rs m27,204123,014 22.1%  
Depreciation Rs m2,46136,328 6.8%   
Interest Rs m1,85921,335 8.7%   
Profit before tax Rs m25,04162,468 40.1%   
Minority Interest Rs m0-256 0.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,4142,627 244.2%   
Profit after tax Rs m17,22459,585 28.9%  
Gross profit margin %40.724.9 163.8%  
Effective tax rate %25.64.2 609.1%   
Net profit margin %25.812.0 214.2%  
BALANCE SHEET DATA
Current assets Rs m46,622434,837 10.7%   
Current liabilities Rs m32,843339,955 9.7%   
Net working cap to sales %20.619.2 107.6%  
Current ratio x1.41.3 111.0%  
Inventory Days Days7478 95.1%  
Debtors Days Days79107 73.6%  
Net fixed assets Rs m39,029114,429 34.1%   
Share capital Rs m84617,491 4.8%   
"Free" reserves Rs m31,4000-   
Net worth Rs m33,890245,875 13.8%   
Long term debt Rs m18,637367,313 5.1%   
Total assets Rs m90,136990,362 9.1%  
Interest coverage x14.53.9 368.4%   
Debt to equity ratio x0.51.5 36.8%  
Sales to assets ratio x0.70.5 148.3%   
Return on assets %21.28.2 259.1%  
Return on equity %50.824.2 209.7%  
Return on capital %48.513.6 356.3%  
Exports to sales %43.30-   
Imports to sales %6.90-   
Net fx Rs m23,1650-   
CASH FLOW
From Operations Rs m27,13265,018 41.7%  
From Investments Rs m-7,014-51,275 13.7%  
From Financial Activity Rs m-14,352-17,132 83.8%  
Net Cashflow Rs m5,767-3,389 -170.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.07 Rs / USD

Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: AJANTA PHARMA  STERLING BIOTECH  NOVARTIS  UNICHEM LAB  ALEMBIC PHARMA  



Today's Market

Of Share Buybacks, GST Cess on Motor Vehicles, and Top Stocks in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Wednesday and finished their session in the green for the second straight session. Heavy buying was seen in realty stocks, metal stocks and bank stocks.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 24, 2017 09:17 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS